ifosfamide

Ifosfamide (NSC-109724) alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. Ifosfamide is a synthetic analog of the nitrogen mustard cyclophosphamide with antineoplastic activity. This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes.

L-Ifosfamide is nitrogen mustard, a chemotherapeutic antineoplastic, and more precisely an alkylating agent structural analog of cyclophosphamide with respect to which presents some differences regard to the antitumor activity and spectrum.

Aldoifosfamide is a metabolite of ifosfamide. Ifosfamide (also marketed as Mitoxana and Ifex) is a nitrogen mustard alkylating agent used in the treatment of cancer. It is sometimes abbreviated 'IFO''.

Palifosfamide (tromethamine), a synthetically derived alkylating agent, exhibits potential antineoplastic properties. Acting as the stabilized active metabolite of ifosfamide, it irreversibly alkylates and crosslinks DNA at GC base pairs, inhibiting DNA replication and inducing cell death. Palifosfamide (tromethamine) boasts reduced toxicity in comparison to ifosfamide.

Palifosfamide (Isophosphamide mustard) lysine (ZIO-201) is a stable form of palifosfamide. Palifosfamide lysine has broad activity in sarcoma lines in vitro. The IC50 ranges from 2.25 to 6.75 μM for most cell lines except OS222 (IC50=31.5 μM).

4-Hydroperoxyifosfamide, an anticancer agent, is capable of penetrating the blood-brain barrier (BBB) [1].

Sodium 2-mercaptoethanesulfonate (Uromitexan) is a sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from antineoplastic agents, such as ifosfamide or cyclophosphamide.